Lactacystin
Modify Date: 2024-01-02 13:00:20
Lactacystin structure
|
Common Name | Lactacystin | ||
|---|---|---|---|---|
| CAS Number | 133343-34-7 | Molecular Weight | 376.425 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 714.9±60.0 °C at 760 mmHg | |
| Molecular Formula | C15H24N2O7S | Melting Point | 233-235ºC dec. | |
| MSDS | Chinese USA | Flash Point | 386.1±32.9 °C | |
Use of LactacystinLactacystin, an antibiotic Streptomyces spp. metabolite, is a potent and selective proteasome inhibitor with an IC50 of 4.8 μM for 20S proteasome. Lactacystin also inhibits the lysosomal enzyme cathepsin A[1]. Lactacystin inhibits cell growth and induces neurite outgrowth[2]. |
| Name | lactacystin |
|---|---|
| Synonym | More Synonyms |
| Description | Lactacystin, an antibiotic Streptomyces spp. metabolite, is a potent and selective proteasome inhibitor with an IC50 of 4.8 μM for 20S proteasome. Lactacystin also inhibits the lysosomal enzyme cathepsin A[1]. Lactacystin inhibits cell growth and induces neurite outgrowth[2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 4.8 μM (proteasome)[1] |
| In Vivo | Lactacystin (microinjection; 2 µg) induces a Parkinson’s disease-like motor phenotype 5-7 days after injection in young and adult mice[2]. Animal Model: Male C57Bl/6RccHsd mice with 8-9 weeks (young) and 12-14 months (adult) old[2] Dosage: 2 µg Administration: Microinjection Result: Induced a Parkinson’s disease-like motor phenotype 5-7 days after injection in young and adult mice. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 714.9±60.0 °C at 760 mmHg |
| Melting Point | 233-235ºC dec. |
| Molecular Formula | C15H24N2O7S |
| Molecular Weight | 376.425 |
| Flash Point | 386.1±32.9 °C |
| Exact Mass | 376.130432 |
| PSA | 178.33000 |
| LogP | -1.10 |
| Vapour Pressure | 0.0±5.2 mmHg at 25°C |
| Index of Refraction | 1.560 |
| Storage condition | −20°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
|
Neuroprotective effect of modified Chungsimyeolda-tang, a traditional Korean herbal formula, via autophagy induction in models of Parkinson's disease.
J. Ethnopharmacol. 159 , 93-101, (2014) Previous studies in our laboratory revealed the neuroprotective effect of modified Yeoldahanso-tang (MYH) in models of Parkinson׳s disease (PD). In this study, we investigated another traditional Kore... |
|
|
Septins arrange F-actin-containing fibers on the Chlamydia trachomatis inclusion and are required for normal release of the inclusion by extrusion.
MBio 5(5) , e01802-14, (2014) Chlamydia trachomatis is an obligate intracellular human pathogen that grows inside a membranous, cytosolic vacuole termed an inclusion. Septins are a group of 13 GTP-binding proteins that assemble in... |
|
|
Development of two novel high-throughput assays to quantify ubiquitylated proteins in cell lysates: application to screening of new anti-malarials.
Malaria Journal 14 , 200, (2015) The ubiquitin proteasome system (UPS) is one of the main proteolytical pathways in eukaryotic cells and plays an essential role in key cellular processes such as cell cycle, stress response, signal tr... |
| L-Cysteine, N-acetyl-S-[[(3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinyl]carbonyl]- |
| (+)-Lactacystin |
| MFCD01076525 |
| N-Acetyl-S-({(2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxopyrrolidin-2-yl}carbonyl)-L-cysteine |
| L-cysteine, S-[[(2R,3S,4R)-3,4-dihydro-3,5-dihydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-2H-pyrrol-2-yl]carbonyl]-N-(1-hydroxyethylidene)-, (E)- |
| L-Cysteine, N-acetyl-S-[[(2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinyl]carbonyl]- |
| LACTACYSTIN |
| N-Acetyl-S-({(3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinyl}carbonyl)-L-cysteine |
| N-Acetyl-S-({(2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinyl}carbonyl)-L-cysteine |